-
Tytuł:
-
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
-
Autorzy:
-
Kerliu L; Sanofi-Genzyme, Cambridge, MA, USA.
Myruski S; Sanofi-Genzyme, Cambridge, MA, USA.
Bhatti A; Sanofi-Genzyme, Cambridge, MA, USA.
Soni P; Sanofi-Genzyme, Cambridge, MA, USA.
Petrosius P; Sanofi-Genzyme, Cambridge, MA, USA.
Pervanas HC; MCPHS University Worcester/Manchester, Worcester, MA, USA.
Horton ER; MCPHS University Worcester/Manchester, Worcester, MA, USA.
-
Źródło:
-
The Annals of pharmacotherapy [Ann Pharmacother] 2020 Oct; Vol. 54 (10), pp. 1010-1015. Date of Electronic Publication: 2020 Mar 16.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Sept. 2013- : Thousand Oaks, CA : Sage
Original Publication: Cincinnati, OH : Harvey Whitney Books Co., c1992-
-
MeSH Terms:
-
Carcinoma, Ovarian Epithelial/*drug therapy
Fallopian Tube Neoplasms/*drug therapy
Indazoles/*therapeutic use
Neoplasm Recurrence, Local/*drug therapy
Ovarian Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Piperidines/*therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use
Carcinoma, Ovarian Epithelial/pathology ; Clinical Trials, Phase III as Topic ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Indazoles/administration & dosage ; Indazoles/adverse effects ; Indazoles/pharmacokinetics ; Middle Aged ; Ovarian Neoplasms/pathology ; Peritoneal Neoplasms/pathology ; Piperidines/administration & dosage ; Piperidines/adverse effects ; Piperidines/pharmacokinetics ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacokinetics ; Progression-Free Survival
-
Contributed Indexing:
-
Keywords: fallopian cancer; ovarian cancer; poly (ADP-ribose) polymerase inhibitors; primary peritoneal cancer
-
Substance Nomenclature:
-
0 (Indazoles)
0 (Piperidines)
0 (Poly(ADP-ribose) Polymerase Inhibitors)
HMC2H89N35 (niraparib)
-
Entry Date(s):
-
Date Created: 20200317 Date Completed: 20201231 Latest Revision: 20201231
-
Update Code:
-
20240105
-
DOI:
-
10.1177/1060028020912749
-
PMID:
-
32172572
-
Objective: To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC).
Data Sources: A literature search via MEDLINE through PubMed from August 2013 to January 2020 was performed using the key terms niraparib, PARP inhibitors, ovarian cancer, fallopian tube cancer , and primary peritoneal cancer .
Study Selection and Data Extraction: Completed and ongoing trials were identified through a review of the website trial registry https://www.clinicaltrials.gov.
Data Synthesis: In a phase III, double-blind clinical trial, progression-free survival improved in patients treated with niraparib compared with placebo as maintenance treatment for patients with platinum-sensitive, recurrent OC: 21 versus 5.5 months in the germline breast cancer susceptibility gene ( gBRCA ) cohort (hazard ratio [HR] = 0.27; 95% CI = 0.17 to 0.41; P < 0.001) and 9.3 versus 3.9 months in the overall nongermline breast cancer susceptibility gene (non- gBRCA ) cohort (HR = 0.45; 95% CI = 0.34 to 0.61; P < 0.001). Adverse events included thrombocytopenia and anemia.
Relevance to Patient Care and Clinical Practice: Poly (ADP-ribose) polymerase (PARP) inhibitors have gained a place in the therapeutic management of OC, FTC, and PPC because of their ability to suppress growth of homologous recombination deficiency-positive tumors, including those with BRCA1/2 mutations. Niraparib inhibits the DNA repair mechanism vital to the survival of cancer cells, poly-ADP ribose polymerase.
Conclusions: PARP inhibitors can be used as a single agent for maintenance therapy for platinum-sensitive recurrent disease in patients with partial or complete response following 2 or more rounds of platinum-based therapy.
